Valiant Organics pharma unit posts Rs 9.40 crore profit

Valiant Organics Limited’s pharma division posted a Rs 9.40 crore segment profit before interest and tax in the quarter ended 30 September 2026, reversing a Rs 2.09 crore loss a year earlier, as revenue increased to Rs 85.83 crore from Rs 32.99 crore. The consolidated segment disclosure also shows pharma revenue above the Rs 55.80 crore recorded in the June 2026 quarter.

How did Valiant Organics’ pharma division perform in September 2026?

Valiant Organics’ pharma division generated revenue of Rs 85.83 crore in the three months ended 30 September 2026, compared with Rs 32.99 crore in the corresponding 2025 quarter and Rs 55.80 crore in the three months ended 30 June 2026. The year-on-year revenue increase was Rs 52.85 crore, while the sequential increase was Rs 30.03 crore.

The pharma division reported a segment profit before interest and tax of Rs 9.40 crore, compared with a Rs 2.09 crore loss in the September 2025 quarter. Its September 2026 result was below the Rs 16.85 crore reported in the June 2026 quarter, despite revenue rising sequentially. The filing does not provide product-level, volume or pricing details to explain the change in the segment result between the two 2026 quarters.

How did Valiant Organics’ operating divisions compare?

Valiant Organics reported consolidated revenue from operations of Rs 304.22 crore in the September 2026 quarter, compared with Rs 157.31 crore a year earlier and Rs 231.54 crore in June 2026. The Speciality Chemical Division remained the larger operating segment, with Rs 218.38 crore of quarterly revenue, while the pharma division contributed Rs 85.83 crore.

The two divisions reported different sequential movements in segment profitability. The Speciality Chemical Division’s result before interest and tax was Rs 20.57 crore in September 2026, down from Rs 25.06 crore in June 2026 but up from Rs 13.77 crore a year earlier. Pharma’s Rs 9.40 crore result took combined segment results to Rs 29.96 crore, compared with Rs 11.68 crore in the September 2025 quarter.

Pharma contributed more of the year-on-year revenue increase in percentage terms, rising from Rs 32.99 crore to Rs 85.83 crore. Speciality chemical revenue increased from Rs 124.32 crore to Rs 218.38 crore over the same comparison. The announcement does not disclose sales volumes, customer concentration or individual product contributions for either operating division.

What do Valiant Organics’ half-year figures show?

Valiant Organics’ pharma division reported Rs 141.64 crore of revenue and Rs 26.25 crore of segment profit before interest and tax for the six months ended 30 September 2026. In the six months ended 30 September 2025, the division recorded Rs 86.71 crore of revenue and a Rs 2.29 crore loss on the same measure.

The Speciality Chemical Division reported half-year revenue of Rs 394.12 crore, compared with Rs 275.00 crore in the prior-year period, and its segment result rose to Rs 45.62 crore from Rs 31.13 crore. Combined segment results reached Rs 71.87 crore in the 2026 half year, compared with Rs 28.84 crore a year earlier, before finance costs of Rs 10.31 crore.

After finance costs and the share of profit of associates, Valiant Organics reported consolidated profit before tax of Rs 61.56 crore for the six months ended 30 September 2026, compared with Rs 18.53 crore a year earlier. Consolidated net profit was Rs 46.56 crore, versus Rs 13.86 crore, while the share of associates’ profit increased to Rs 7.38 crore from Rs 0.69 crore.

What assets and liabilities did Valiant Organics report for pharma?

Valiant Organics reported pharma division assets of Rs 585.63 crore at 30 September 2026, compared with Rs 552.63 crore at 30 June 2026 and Rs 529.35 crore at 30 September 2025. The segment’s assets were therefore Rs 56.28 crore higher than a year earlier. Speciality Chemical Division assets increased to Rs 743.34 crore from Rs 627.38 crore over the same year-on-year comparison.

Pharma division liabilities were Rs 298.92 crore at 30 September 2026, compared with Rs 229.29 crore at 30 June 2026 and Rs 128.24 crore a year earlier. The segment statement also reported unallocated corporate liabilities of Rs 794.47 crore, alongside total consolidated assets of Rs 1,335.20 crore at the September 2026 date.

At the consolidated balance-sheet level, total assets stood at Rs 1,335.20 crore on 30 September 2026, compared with Rs 1,230.79 crore on 31 March 2026. Trade receivables increased to Rs 320.33 crore from Rs 243.31 crore, while inventories rose to Rs 110.98 crore from Rs 91.52 crore. These changes occurred during a half year in which revenue from operations reached Rs 535.76 crore.

How did Valiant Organics’ cash flow and review compare?

Valiant Organics generated Rs 22.84 crore of net cash from operating activities in the six months ended 30 September 2026, compared with Rs 92.24 crore in the prior-year half year. The cash-flow statement recorded a Rs 79.61 crore increase in trade receivables in the 2026 period, whereas receivables decreased by Rs 21.89 crore in the 2025 comparative period.

The group spent Rs 25.29 crore on fixed assets, including capital work-in-progress, during the 2026 half year, compared with Rs 12.49 crore a year earlier. Net cash used in investing activities was Rs 11.37 crore, against Rs 70.24 crore in the prior-year period, while net cash used in financing activities was Rs 6.75 crore compared with Rs 23.08 crore.

Consolidated cash and cash equivalents closed at Rs 6.52 crore on 30 September 2026, compared with Rs 1.79 crore at 31 March 2026. Gokhale & Sathe LLP issued its limited-review report on 5 November 2026 and said nothing had come to its attention indicating required disclosures were absent or that the statement contained a material misstatement. The auditor also stated that a review is substantially less extensive than an audit and does not provide audit assurance.

Conclusion

Valiant Organics’ September 2026 segment disclosure shows that the pharma division moved from a Rs 2.09 crore loss to a Rs 9.40 crore profit before interest and tax while revenue reached Rs 85.83 crore. The Speciality Chemical Division remained the larger revenue business at Rs 218.38 crore, but pharma’s return to profit contributed to combined segment results of Rs 29.96 crore for the quarter.

What to watch next is whether the pharma division sustains positive segment profitability after its result declined from Rs 16.85 crore in June 2026 to Rs 9.40 crore in September 2026. The filing does not provide product-level explanations or an outlook, while the increase in consolidated trade receivables to Rs 320.33 crore and the reduction in half-year operating cash flow to Rs 22.84 crore remain disclosed matters for subsequent results.